



(Translation)

PATENT OFFICE  
JAPANESE GOVERNMENT

This is to certify that the annexed is a true copy of the following application as filed with this Office.

Date of Application: December 26, 1997

Application Number: Japanese Patent Application  
No.361022/1997

Applicant(s): KIKKOMAN CORPORATION

Commissioner,  
Patent Office

Takeshi ISAYAMA (seal)

[Document] Patent Application

[Reference Number] P97-0496

[Filing date] December 26, 1997

[Addressee] Comissioner of Patent Office

[IPC] C12N 9/02

[Title of the Invention] LUCIFERASE AND METHODS FOR MEASURING  
INTRACELLULAR ATP USING THE SAME

[Number of claims] 13

[Inventor]

    [Address or Residence] c/o KIKKOMAN CORPORATION, 339, Noda,  
Noda-shi, Chiba 278-0037, Japan

    [Name] Noriaki HATTORI

[Inventor]

    [Address or Residence] c/o KIKKOMAN CORPORATION, 339, Noda,  
Noda-shi, Chiba 278-0037, Japan

    [Name] Seiiji MURAKAMI

[Applicant]

    [Identification Number] 000004477

    [Name] KIKKOMAN CORPORATION

[Agent]

    [Identification Number] 100091096

    [Patent Attorney]

    [Name] Yusuke HIRAKI

[Agent]

    [Identification Number] 100096183

    [Patent Attorney]

    [Name] Sadaji ISHII

[Indication of Fees]

    [Deposit Ledger No.] 015244

    [Amount Paid] 21000

[List of Attached Documents]

    [Name of Document] Specification 1

[Name of Document]

Drawing 1

[Name of Document]

Abstract 1

[Necessary of Proof]

Necessary

[Document Name] Specification

[Title of the Invention] Luciferase and Methods for Measuring Intracellular ATP using the same

[Claim]

[Claim 1] A luciferase having resistance to a surfactant.

[Claim 2] The luciferase of claim 1 wherein an amino acid corresponding to that at the 490-position of luciferase from Genji or Heike firefly is substituted by an amino acid other than glutamic acid in the amino acid sequence of firefly luciferase.

[Claim 3] The luciferase of claim 2 wherein the amino acid other than glutamic acid is lysine.

[Claim 4] The luciferase of claim 1 wherein it is:

(a) a polypeptide consisting of the amino acid sequence shown in SEQ ID NO:4; or  
(b) a polypeptide comprising additions, deletions or substitutions of one or more amino acids in the amino acid sequence of the polypeptide defined in (a) and having luciferase activity resistant to a surfactant.

[Claim 5] The luciferase of claim 1 wherein it is:

(a) a polypeptide consisting of the amino acid sequence shown in SEQ ID NO:6; or  
(b) a polypeptide comprising additions, deletions, or substitutions of one or more amino acids in the polypeptide defined in (a) and having luciferase activity resistant to a surfactant.

[Claim 6] A luciferase gene encoding the luciferase of any one of claim 1 to 5.

[Claim 7] A recombinant vector comprising the luciferase gene of claim 6.

[Claim 8] A transformant comprising the recombinant vector of claim 7.

[Claim 9] A method for producing a luciferase wherein the method comprising culturing the transformant of claim 8 in a medium and recovering the luciferase from the resulting culture.

[Claim 10] A method for measuring intracellular ATP characterized in that a luciferase having resistance to a surfactant is used as a luciferase for use in the method comprising a first step wherein ATP is extracted in the presence of the surfactant from cells in a sample, a second step wherein a luminescence reagent containing luciferase is added to the extracted ATP solution to cause emission of light, and a third step wherein the amount of light emission is measured.

[Claim 11] The method for measuring intracellular ATP of claim 10 wherein the luciferase having resistance to a surfactant is a luciferase of any one of claim 1 to 5.

[Claim 12] The method for measuring intracellular ATP of claim 10 or 11 wherein the light emission is caused by addition of a luminescence reagent in the presence of a surfactant of 0.01% or more.

[Claim 13] The method for measuring intracellular ATP of claim 10, 11 or 12 wherein the surfactant is any of a cationic surfactant, an anionic surfactant, a nonionic surfactant, and an amphoteric surfactant.

[Detailed Description of the Invention]

[0001]

[Field of the Invention]

The present invention relates to novel luciferase and a method for measuring intracellular ATP using the same.

[0002]

[Prior Art]

Intracellular ATP is routinely measured for determining the presence of cells in a sample or the number of cells in the fields of food sanitation, biology, clinical examinations, medical science, ultrapure water, and environmental science. A general method for measuring intracellular ATP comprises the steps of adding an ATP extraction reagent containing a surfactant as an effective component to a sample containing cells, extracting intracellular ATP, adding a luminescence reagent containing luciferase into the sample, and then measuring the total amount of light emitted.

[0003]

Luciferase is an enzyme that catalyzes luminescence reaction of luciferin, which is a substrate, in the presence of ATP and magnesium ion. Luciferase used in a method for measuring intracellular ATP includes those derived from firefly species, such as GENJI firefly (*Luciola cruciata*), HEIKE firefly (*Luciola lateralis*), North American firefly and Russian firefly, etc.

[0004]

Intracellular ATP can be extracted by adding an ATP extraction reagent to a sample containing cells and then stirring the sample.

To make full use of the capabilities of the extraction reagent, preferably the reaction agent is added so that the concentration of a surfactant becomes 0.05% or more of the mixture of the sample and the extraction reagent. However, a condition where the concentration of the surfactant is 0.05% or more, this inhibits significantly the enzyme reaction in the process of measuring ATP concentration by bioluminescence. Thus the sensitivity and accuracy of measurement are largely impaired. This is because a surfactant at such a high concentration lowers luciferase activity. For example, North American firefly luciferase activity decreases to about 20% in the presence of 0.1% benzalkonium chloride (See Table 1).

On the other hand, inhibition of the bioluminescent reaction can be reduced with a lower concentration of surfactant. However, in this case the extraction efficiency for ATP would be insufficient.

[0005]

A method wherein cyclodextrin or its derivative is used is a known method for suppressing the inhibition of luminescence reaction by a surfactant (Japanese Patent Application Laid-Open No. 6-504200).

Among methods for measuring intracellular ATP wherein intracellular ATP is extracted by allowing a sample to contact with a surfactant and subsequently ATP

is measured by luciferin-luciferase bioluminescent reaction method, a method for measuring intracellular ATP characterized by the application of the bioluminescent reaction method after allowing a sample, from which ATP is extracted, to contact with cyclodextrin (Japanese Patent Application Laid-Open Publication No. 7-203995) is also known.

There has been no attempt so far to suppress the inhibition of bioluminescent reaction due to a surfactant focusing on luciferase.

[0006]

[Problems to be Solved by the Invention]

Thus, the purpose of the invention is to provide a novel luciferase having anti-surfactant resistance, whose activity is not impaired by the presence of a surfactant at a high concentration. The other purpose of the invention is to provide a method, comprising the steps of extracting intracellular ATP using a surfactant and measuring intracellular ATP by bioluminescent reaction using a luciferase, which can lower the inhibition of bioluminescent reaction due to a surfactant without a decrease in efficiency in extracting intracellular ATP.

In the context of this Specification, the term "suppress" is used to describe significant reduction of the inhibition of the luminescence reaction by a surfactant and the complete elimination of this inhibition.

[0007]

[Means for Solving the Problem]

The present invention relates to a luciferase having anti-surfactant resistance.

The luciferase having resistance to a surfactant includes a luciferase, wherein an amino acid at the 490-position, or an amino acid corresponding to the amino acid at 490-position of GENJI firefly or HEIKE firefly is substituted by an amino acid other than glutamic acid, e.g., lysine, in the amino acid sequence of a wild-type firefly luciferase.

[0008]

Further, the luciferase having resistance to a surfactant includes a polypeptide consisting of (a) or (b):

(a) A polypeptide consisting of the amino acid sequence shown in SEQ ID NO:4,  
(b) A polypeptide comprising additions, deletions, or substitutions of one or more of amino acids in the polypeptide of (a), and having luciferase activity resistant to a surfactant, or

a polypeptide consisting of (a) or (b):

(a) A protein consisting of an amino acid sequence shown in SEQ ID NO:6,  
(b) A protein comprising additions, deletions, or substitutions of one or more of amino acids in the polypeptide of (a), and having luciferase activity resistant to a surfactant.

[0009]

Further, the present invention relates to a luciferase gene encoding the luciferase having resistance to a surfactant.

Furthermore, the present invention relates to a recombinant vector containing the

luciferase gene encoding the luciferase having resistance to a surfactant. The present invention also relates to a transformant containing the recombinant vector.

[0010]

In addition, the present invention relates to a method for producing the luciferase, comprising the steps of culturing the recombinant in a medium, and collecting luciferase with resistance to a surfactant from the culture product.

Moreover the present invention relates to a method for measuring intracellular ATP, comprising the steps of a first step wherein ATP is extracted in the presence of a surfactant from cells in a sample; a second step wherein a luminescence reagent containing luciferase is added to the extracted ATP solution so as to cause light emission; and a third step wherein the light emission is measured, and characterized in that luciferase having resistance to a surfactant is used.

[0011]

[Embodiments of the Invention]

The present invention will now be described in detail.

[Luciferase having resistance to surfactant]

Luciferase having resistance to a surfactant according to the present invention is as described below.

The term "having resistance to a surfactant" corresponds to any one of the following features.

(1) When compared to known luciferase, the luciferase of the present invention leads to an increased initial amount of light emitted in the presence of a surfactant. Here the term "compare" means, for example, where the luciferase of the present invention is produced by introducing mutation into an amino acid sequence of known luciferase, to compare light emission from luciferase before and after the introduction of a mutation.

(2) When compared to known luciferase, the luciferase of the present invention shows a gentle decrease in its activity in the presence of a surfactant.

(3) The luciferase of the present invention has the remaining activity of more than 85% in the presence of 0.4% surfactant.

[0012]

Hereinafter "luciferase having resistance to a surfactant" is referred to as "surfactant-resistant luciferase."

The term "activity" means the catalytic activity of bioluminescent reaction. Further any surfactant can be used in the present invention so far as it can be used in the measurement system for intracellular ATP. These surfactants include an anionic surfactant, cationic surfactant, ampholytic surfactant, non-ionic surfactant. A specific reagent is benzalkonium chloride or benzetonium chloride containing quaternary ammonium salt as a major component.

[0013]

The luciferase of the present invention can be prepared from luminescence organs

of luminescent organisms. The luminescent organisms include luminescent insects and luminescent bacteria. The luminescent insects include those belonging to the order Cleoptera, such as those belonging to the family firefly and the family Pyrophorus. Specific examples include GENJI firefly, HEIKE firefly, North American firefly, Russian firefly, Pynophorus plagiophthalmus, Arachnocampa luminosa, and Rail worm. Further the luciferase of the present invention is obtained by cloning a luciferase gene from the luminescent organism and allowing the gene to express using an appropriate vector - host system.

[0014]

Moreover, the luciferase of the present invention can be obtained by introducing mutation such as additions, deletions, and substitutions into an amino acid sequence of well-known luciferase. Well-known genetic engineering techniques can be used to introduce mutation into an amino acid sequence. In this case firstly, a mutation such as an addition, deletion, or substitution is introduced into a nucleotide sequence of a luciferase gene derived from the abovementioned luminescent organism or a well-known luciferase gene by genetic engineering techniques so as to generate a mutant luciferase gene. Subsequently, the mutant gene is incorporated into an appropriate host-vector system, thereby generating a recombinant microorganism. Then the recombinant microorganisms producing the luciferase of the present invention are selected by screening. The selected recombinant microorganisms are cultured in a medium. Finally the luciferase can be collected from the culture product.

[0015]

Hereinafter surfactant-resistant luciferase obtained by introduction of a mutation into an amino acid sequence is referred to as "mutant luciferase."

The mutant luciferase is for example, luciferase wherein an amino acid corresponding to an amino acid at the 490-position of the GENJI firefly luciferase or the HEIKE firefly luciferase, is substituted by an amino acid other than glutamic acid in an amino acid sequence of a wild-type firefly luciferase. The amino acid other than glutamic acid is a basic amino acid. Specific examples include lysine, arginine, and histidine. The term "an amino acid corresponding to the amino acid at the 490-position of the GENJI or the HEIKE firefly luciferase" means an amino acid corresponding to the amino acid at the 490-position of the GENJI or HEIKE firefly luciferase when the determined amino acid sequence of luciferase is compared to an amino acid sequence of the GENJI or HEIKE firefly luciferase.

[0016]

Moreover, in the GENJI or HEIKE firefly luciferase, the amino acid at the 490-position is glutamic acid. Further, in North American firefly luciferase, "an amino acid corresponding to the amino acid at the 490-position of the GENJI or the HEIKE firefly luciferase" corresponds to the glutamic acid at the 487-position. More specifically, the mutant luciferase is a polypeptide comprising an amino acid sequence shown in SEQ ID NO:1 or 2, or said amino acid sequence wherein one or



more amino acids are added, deleted or substituted.

[0017]

[Method for producing mutant luciferase by genetic engineering techniques]

A method for generating mutant luciferase by genetic engineering techniques will now be described as follows.

The mutant luciferase is produced by introducing mutation such as additions, deletions, and substitutions into a nucleotide sequence of known luciferase and allowing an appropriate vector-host system to express the gene.

[0018]

The known luciferase genes includes, but are not limited to, a firefly luciferase gene, more specifically a wild-type HEIKE firefly luciferase gene (Japanese Patent Application Laid-Open No. 2-171189) and a thermostable HEIKE firefly luciferase gene (Japanese Patent Application Laid-Open No. 5-244942).

A method for introducing mutation into a luciferase gene is, for example a method wherein the gene and a mutagen are allowed to contact with each other. Specific examples of the mutagen include hydroxylamine, nitrous acid, sulfurous acid, and 5-bromouracil. Further, ultra violet irradiation, cassette mutagenesis, and site-directed mutagenesis using PCR can also be used. Furthermore, a mutant luciferase gene having a mutation at a desired position can be generated by annealing chemically synthesized DNA.

[0019]

Next, the mutant luciferase gene is inserted into a vector DNA having such as a promoter sequence, a marker gene, and a replication origin, etc, thereby producing a recombinant plasmid. Any vector DNA can be used so far as it can be replicated in a host cell. Examples of the vector DNA include plasmid DNA and bacteriophage DNA. When the host cell is *Escherichia coli*, examples of the vector DNA include plasmid pUC119 (Takara Shuzo Co., Ltd.), pBluescript SK+(Stratagene), pMAL-C2 (NEW England Labs), pGEX-5X-1 (Pharmacia), pXa1 (Boehringer), and pMA56 (G.Ammerer, Meth. Enzymol., 101, 192, 1983).

[0020]

Subsequently, an appropriate host cell is transformed or transduced with the above recombinant plasmid, and screening is performed for recombinant microorganisms having the ability to produce the mutant luciferase.

Any host cells including eucaryotic and prokaryotic cells can be used. The eucaryotic cells include animal, plant, insect, yeast cells. The prokaryotic cells include *Escherichia coli*, *Bacillus subtilis*, and *Actinomyces*. The animal cells include CHO, COS, HeLa cells and cells of myeloma cell lines. The prokaryotic cells include microorganisms belong to the genus *Escherichia*, such as *Escherichia coli* JM101 (ATCC 33876), JM109 (produced by Takara Shuzo Co., Ltd.), XL1-Blue (produced by Stratagene), and HB101 (ATCC33694).

[0021]

Transformation in the present invention can be performed by for example, D.M.

Morrison's method (Meth. Enzymol., 68, 326-331, 1979); Transduction can be conducted by for example, B.Hohn's method (Meth. Enzymol., 68, 299-309, 1979). Methods for purification of recombinant DNA from recombinant microorganisms include P.Guerry's method (J.Bacteriology, 116, 1064-1066, 1973), and D.B.Clewell's method (J.Bacteriology, 110, 667-676, 1972).

The nucleotide sequence of a gene inserted into the recombinant DNA can be determined by, for example Maxam-Gilbert method (Proc. Natl. Acad. Sci. USA, 74, 560-564, 1977), and Dideoxy method (Proc. Natl. Acad. Sci. USA, 74, 5463-5467, 1977).

[0022]

The mutant luciferase of the present invention can be produced by culturing the recombinant microorganisms obtained in the manner described above in media.

When the host cell is *Escherichia coli*, recombinant *E.coli* may be cultured by solid culture methods, preferably liquid culture methods.

A culture medium of the present invention contains one or more nitrogen sources, such as yeast extract, tryptone, peptone, meat extract, corn steep liquor or exudate of soy bean or wheat bran, to which one or more of inorganic salts, such as sodium chloride, potassium phosphate, dipotassium phosphate, magnesium sulfate, magnesium chloride, ferric chloride, ferric sulfate or manganese sulfate are added. If necessary sugar and vitamins are added to this medium. Further the initial pH of the medium is preferably adjusted within pH 7 to 9. Moreover the culture is performed at a temperature within 30°C to 42°C, preferably at around 37°C for 3 to 24 hours, preferably for 5 to 8 hours. Preferable culture methods include aeration-agitation submerged culture, shaking culture, and static culture.

[0023]

To recover mutant luciferase from the culture product after the completion of culturing recombinant *E.coli*, standard means for collecting enzymes can be employed. That is, the culture product is centrifuged to obtain cells. Then the cells are disrupted by treatment with lytic enzymes, such as lysozyme, ultrasonication, or milling. Fused protein is discharged out of the cell. Subsequently insoluble substances are removed by filtration or centrifugation, so that a crude enzyme solution containing mutant luciferase can be obtained.

[0024]

In the present invention the above crude enzyme solution can be used as authentic protein matter, or alternatively it can further be purified to higher purity by standard protein purification techniques. These techniques including sulfate salting out, organic solvent precipitation, ion exchange chromatography, hydrophobic chromatography, gel filtration chromatography, adsorption chromatography, affinity chromatography, and electrophoresis can be used solely or in combination.

The use of surfactant-resistant luciferase of the present invention allows the

addition of a surfactant at a high concentration in the extraction process for intracellular ATP.

[0025]

[Detection of intracellular ATP of the present invention]

Detection of intracellular ATP of the present invention will be described as follows.

First, ATP extraction reagent containing surfactant as an effective component is added to a sample containing cells so as to extract intracellular ATP out of the cells. The term "cells" refers to the cells derived from animal, plant, microorganism (e.g., yeasts, mold, fungi, bacteria, actinomyces, unicellular algae, viruses, and protozoa).

[0026]

Any sample can be used so far as it contains the above cells. These samples include, but are not limited to, foods and drinks, pharmaceuticals, cosmetics, seawater, river water, industrial water, sewage, soil, urine, feces, blood, sputum, pus, and culture product of the above cells. A sample solution can also be prepared by suspending these samples in an appropriate solvent, such as distilled water, physiological saline, phosphoric acid buffer, Tris buffer, or sodium acetate buffer. When a fluid specimen contains solids, the fluid specimen is suspended in an appropriate solvent or homogenized using a mixer so that it can be handled in the same manner as that in liquid form.

[0027]

A sample of a filter membrane can also be prepared by filtering the above sample in liquid form through a hydrophilic or hydrophobic filter membrane.

The hydrophilic or hydrophobic filter membrane by which cells are captured can be used as a sample. In such a case, a film- or sheet-type hydrophilic filter membrane made of hydrophilic polytetrafluoroethylene, hydrophilic polyvinylidene fluoride, hydrophilic polyamide, acetylcellulose, and nitrocellulose, etc., can be used. Hydrophobic filter membranes made of PVDF (polyvinylidene fluoride), PTFE (polytetrafluoroethylene), and PE (polyethylene) etc., can be used.

[0028]

Surfactants include anionic surfactants, cationic surfactants, ampholytic surfactants, and non-ionic surfactants.

Anionic surfactants include sodium dodecyl sulfate (SDS), lauryl potassium sulfate, sodium monolauroyl phosphate, and sodium alkylbenzenesulfonic acid. Cationic surfactants include benzalkonium chloride (BAC), benzetonium chloride (BZC), cetylpyridinium chloride, cethyltrimethylammonium bromide, and myristyldimethylbenzylammonium chloride. ampholytic surfactants include Twittergent Detergent 3-08, 3-10, 3-12, 3-14, 3-16, and Tego. Finally non-ionic surfactants include Tween 20, 60, and 80, Span 60 and 80, Triton X-45 and x-100, polyoxyethylene ether, and polyoxyethylene lauryl ether.

[0029]

Any concentration of a surfactant can be employed so far as it allows full expression of the ability to extract ATP. Preferable concentration of a surfactant is 0.05% or more of the mixture of a sample and ATP extraction reagent. A sample and ATP extraction reagent are contacted with from each other at room temperature or with heating.

[0030]

After ATP extraction, bioluminescent reagent is added to the sample containing surfactant-resistant luciferase so as to cause emission. Then the light emission is measured.

When surfactant-resistant luciferase is derived from a firefly, the bioluminescent reagents are those containing e.g., the following components (a) to (c).  
surfactant-resistant luciferase

luciferin

magnesium ions or other metal ions

Further in addition to the above components, substances involving pH preparation or improved shelf life may be added. Such substances include EDTA 2Na, dithiothreitol, ammonium sulfate, sucrose, 2-mercaptoethanol, HEPES, Tricine, and Tris.

[0031]

iii) The amount of light emitted by the addition of a bioluminescent reagent can be measured by a luminometer such as a lumitester K-100 produced by Kikkoman Corporation, a luminescence reader BLR-201 produced by Aloka Co., Ltd. (an improved type, or a Lumat LB9501 produced by Berthold. When a filter membrane by which cells are captured is used as a sample, the cells can be counted using a bioluminescent image analysis system device to photograph spots on the filter membrane. Such a device is ARGUS-50/CL (with taper fiber: produced by Hamamatsu Photonics K.K.).

[0032]

[Examples]

The present invention will now be described in detail by the use of examples. However the technical field of the present invention is not limited by these examples.

**Example 1** Surfactant resistance of natural type luciferase derived from various fire fly species.

(Method of preparing wild type luciferase derived from various firefly species)

Luciferase derived from GENJI and HEIKE fireflies was prepared according to the following methods. 1 mM ethylene diamine-4-acetate-2-sodium and 2mM phenylmethylsulfonylfluoride were added to 25mM Tris (hydroxy) aminomethane-hydrochloric acid buffer. Further ammonium sulfate was added to this solution so as to achieve 10% saturation. Tail portions of the various firefly species were added to this mixture at pH 7.8, and then disrupted using Hiskotoron (produced by Nichionrikakikaiseisakusho) . The resulting solution was centrifuged at 12,000 r.p.m. for 20 minutes to obtain supernatants as starting

materials for purification. The purification was conducted by the process comprising salting out of ammonium sulfate, Ultrogel Ac A34 (produced by LKB) column, and hydroxy-apatite HPLC (produced by TOSHOH, TSK gel HA-1000) column. Finally an electrophoretically homogenous sample was obtained. In addition the luciferase derived from North American firefly is a commercial product (Sigma, L-9506).

[0033]

(Method of determining luciferase activity)

A luciferase sample was properly diluted using enzyme-diluted solution (1mM EDTA, 1mM 2-mercaptoethanol, 1% BSA, 50mM HEPES, (pH7.5)). To 100  $\mu$ l of this solution, 100  $\mu$ l of substrate solution (1.4mM luciferin, 40mM ATP, 300mM MgSO<sub>4</sub> · 7H<sub>2</sub>O, 50mM HEPES, (pH 7.5)) was added.

The light emission was measured using BLE-201 Luminescence reader (produced by Aloka Co., Ltd.) under the following conditions.

Measuring range: x100

Numerical value displayed: x1000

Measuring temperature: 30°C

Measuring time: 20 seconds

1MLU (mega light unit) /ml is a value for activity when the measured value under these conditions was 1 Kcount.

[0034]

(Method of determining surfactant-resistance)

Enzyme samples were obtained by preparing luciferase samples derived from various firefly species using enzyme-diluted solution (1mM EDTA, 1mM 2-mercaptoethanol, 5% glycerol, 50mM HEPES, (pH7.5)) to achieve 0.5 MLU/ml concentration.

50  $\mu$ l of 0.4% benzalkonium chloride (25mM Tricine at pH 7.75) and then 50  $\mu$ l of the enzyme sample were added to 100  $\mu$ l of substrate solution (4mM ATP, 0.4mM luciferin, 10mM magnesium sulfate, 50mM HEPES (pH 7.5)). After the solution was stirred for 5 seconds, the light emission was measured every second using Berthold Lumat LB-9501 for 1 minute.

[0035]

Figure 2 shows the results. Along the vertical axis in this figure, the relative ratio of the light emission was plotted with the initial amount of light emitted considered to be 100% upon use of 25mM Tricine (pH 7.75) instead of 0.4% benzalkonium chloride.

As shown in these results, North American firefly luciferase was low in the initial light emission and the light emission decayed rapidly. This was caused by the low surfactant-resistance of the North American firefly luciferase. This can lead to low sensitivity and accuracy in measuring such values. On the other hand, GENJI firefly luciferase showed an initial light emission higher than that of

North American firefly luciferase. That is, GENJI firefly luciferase was shown to have a surfactant resistance superior to that of North American firefly luciferase. Furthermore, HEIKE firefly luciferase showed an initial light emission higher than that of GENJI firefly luciferase and the emission decayed slowly. Therefore, HEIKE firefly luciferase has good surfactant resistance, superior to that of GENJI firefly luciferase. These results suggest that the degree of surfactant resistance of luciferase varies according to the firefly species.

[0036]

#### **Example 2 Preparation of mutant luciferase HLK and HIK**

Two types of mutant luciferase (named "HLK" and "HIK") were prepared according to the following methods.

(Production of a gene encoding mutant luciferase HLK)

A mutant luciferase gene was produced by site-directed mutagenesis using PCR. A plasmid pHLf7-217Leu described in Japanese Patent Application Laid-Open No. 5-244942 was used as a template for PCR reaction. The pHLf7-217Leu was a recombinant plasmid prepared by inserting a thermostable HEIKE firefly luciferase gene, in which an amino acid corresponding to Ala at the 217-position was substituted for a Leu-encoding gene, into a plasmid pUC119. In addition, E. coli JM101, to which the recombinant plasmid pHLf7-217Leu had been introduced, has been named E.coli JM101 (pHLf7-217Leu) and was deposited on April 22, 1992 as FERM BP-3840 with the National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology (1-3, Higashi 1-chome, Tsukuba-shi, Ibaraki-ken, Japan).

[0037]

The primer for PCR reaction was an oligonucleotide having a nucleotide sequence shown in SEQ ID No: 1 or 2. The DNA polymerase was a KOD dash polymerase (produced by TOYOBO). A PCR reaction cycle (94°C for 30 seconds, 50°C for 2 seconds, and 74°C for 3 minutes) was repeated for 30 times according to the examples attached to KOD dash polymerase. The PCR product was ligated into a circular recombinant plasmid pHLfLK using standard techniques.

[0038]

Sequencing of a mutant luciferase gene contained in the pHLfLK was performed. Reaction was conducted using a Diprimer Taq Sequencing Kit (produced by Applied Biosystems). Then the electrophoretic analysis was performed using ABI 373A DNA sequencer (produced by Applied Biosystems). The entire nucleotide sequence of the obtained mutant luciferase gene is shown in SEQ ID NO: 3, and the amino acid sequence of a polypeptide encoded by this gene is shown in SEQ ID NO: 4. In the mutant luciferase gene, the genetic portion corresponding to alanine at the 217-position of wild-type HEIKE firefly luciferase was substituted by a gene encoding leucine, the genetic portion corresponding to glutamic acid at the 490-position of the same was substituted by a gene encoding lysine.

[0039]

The pHLfLK-introduced E.coli JM109 strain was named E.coli JM109 (pHLfLK)

(see Figure 1). *E. coli* JM109 (pHLfLK) was deposited as FERM BP-6147 on October 16, 1997) with the National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology, Japan. The polypeptide shown in SEQ ID NO:4 was named the mutant luciferase HLK.

[0040]

(Preparation of gene encoding mutant luciferase HIK)

A mutant luciferase gene was prepared using the plasmid pHLf7-217Ile described in Japanese Patent Application Laid-Open No. 5-244942. The plasmid pHLf7-217Ile was a recombinant plasmid prepared by inserting a thermostable HEIKE firefly luciferase gene, in which an amino acid corresponding to Ala at the 217-position was substituted for a Ile-encoding gene, into a plasmid pUC119. The transformant strain obtained using this plasmid was deposited on April 22, 1992 as FERM BP-3841 with the National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology, Japan.

[0041]

About a 560bp fragment obtained by cutting the pHLfLK with EcoRV and NarI was obtained by agarose gel electrophoresis. Then the fragment was inserted into the pHLf7-217Ile treated with the same restriction enzymes.

The resulting recombinant plasmid has been named pHLfIK and the plasmid-introduced *E. coli* JM109 strain has been named *E. coli* JM109 (pHLfIK). *E. coli* JM109 (pHLfIK) was deposited on October 16, 1997 as FERM BP-6146 with the National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology, Japan.

[0042]

The entire nucleotide sequence of the mutant luciferase gene contained in the pHLfIK is shown in SEQ ID NO: 5, and the amino acid sequence of a polypeptide encoded by this gene is shown in SEQ ID NO: 6. In the mutant luciferase gene, the genetic portion corresponding to alanine at the 217-position of wild-type HEIKE firefly luciferase was substituted by a gene encoding isoleucine, the genetic portion corresponding to glutamic acid at the 490-position of the same was substituted by a gene encoding lysine (see Fig. 1).

A polypeptide shown in SEQ ID NO:6 was named the mutant HIK firefly.

[0043]

### Example 3 Preparation of mutant luciferase HLK and HIK

*E. coli* JM109 (pHLfLK) and *E. coli* JM109 (pHLfIK) were inoculated on LB media (1% Bacto-trypton (W/V), 0.5% yeast extract (W/V), 0.5% NaCl (W/V), ampicillin (50  $\mu$ g/ml), 1.4% agar (W/V)), each containing ampicillin, and cultured at 37°C for 18 hours. The resulting culture fluid was centrifuged at 8000 r.p.m. for 10 minutes. The precipitated cells were suspended in 0.1M potassium phosphate buffer at pH 7.8 (0.1M ammonium sulfate, 1mM EDTA) were disrupted by ultrasonication.

Next, crude enzyme solution was obtained by centrifugation at 12000 r.p.m. for 10 minutes. The obtained enzyme solution was purified using the above

purification techniques such that it becomes an electrophoretically homogenous sample.

[0044]

#### Example 4 Surfactant resistance of mutant luciferase HLK and HIK

(Changes in emission with time)

To compare surfactant resistance of mutant luciferase with that of known luciferase, changes in emission with time measured are shown in figure 3.

"HEIKE I mutant" in this figure is thermostable HEIKE firefly luciferase (described in Japanese Patent Application Laid-Open No. 5-244942) wherein Ala at the 217-position of wild-type HEIKE firefly luciferase is substituted for Ile. "HEIKE L mutant" is thermostable HEIKE firefly luciferase (Japanese Patent Application Laid-Open No. 5-244942) wherein Ala at the 217 position of wild-type HEIKE luciferase is substituted by Leu. "HIK" is the mutant luciferase HIK prepared in Example 4. "HLK" is the mutant luciferase HLK prepared in Example 4.

[0045]

HIK is a mutant wherein Glu at the 490-position of HEIKE I mutant is substituted for Lys. The emission of HIK decayed more slowly than that of the HEIKE I mutant.

HLK is a mutant wherein Glu at the 490-position of HEIKE L mutant is substituted for Lys. Comparison of HLK and HEIKE L mutant reveals that HLK had improved initial light emission, and slower decay in the light emission.

[0046]

Furthermore, mutant luciferase HLK and HIK have slower decay of emission than wild-type and thermostable HEIKE firefly luciferase. Particularly, the initial light emission of HLK improved by about 20%. This indicates that HLK has stronger resistance than HIK

[0047]

(Comparison of emission rate)

The influence of the enzyme solution, substrate solution and benzalkonium chloride used when measuring change with time, on the measurement values taken under actual emission measurement conditions, was examined. Table 1 shows the light emission measured using Berthold Lumat LB-9501 under measuring conditions (5 seconds of waiting time, 3 seconds of measuring time).

In addition, the emission rate (remaining activity) was calculated by dividing the light emission measured in the presence of 0.4% benzalkonium chloride by a control value. Here the control value was the light emission upon use of 25mM Tricine at pH 7.75 instead of 0.4% benzalkonium chloride.

[0048]

Table 1

Luciferase type	Light emission (RLU)	Emission rate (%)



	Without extraction reagent	With extraction reagent	
North American firefly	452563	97790	21.6
GENJI firefly	409406	167805	41.0
HEIKE firefly	425792	324724	76.3
HEIKE I mutant	422269	341039	80.8
HEIKE L mutant	423728	343634	81.1
HIK	386429	345159	89.3
HLK	390289	396764	101.7

[0049]

North American firefly luciferase showed an emission rate as low as 21.6%, suggesting a large decrease in sensitivity. On the other hand, the emission rates for GENJI and HEIKE firefly luciferase were 41.0% and 76.3%, respectively, suggesting that the sensitivity of these firefly luciferases were less affected than that of North American firefly luciferase.

The emission rate for mutant luciferase HIK and HLK were 89.3% and 101.7%, respectively. These rates were far greater than those of wild-type HEIKE firefly luciferase and thermostable HEIKE firefly luciferase. Particularly the emission rate of HLK was almost 100%. That is, HLK can yield the same light emission regardless of the presence or absence of a surfactant. Therefore, the sensitivity of HLK is totally unaffected by the use of a surfactant, allowing measurement with high accuracy.

[0050]

(Comparison of IC<sub>50</sub>)

Benzalkonium chloride and various luciferases were contacted with each other for 10 minutes. Then the benzalkonium chloride concentration (IC<sub>50</sub>), at which activity is inactivated by 50% was determined. Equal amounts of luciferase solution prepared at this concentration and 0.01 to 0.1% benzalkonium chloride were mixed, and then allowed to stand for 10 minutes at room temperature. Subsequently, 100  $\mu$ l of substrate solution was added to the mixture. Immediately after addition, the light emission was measured using Berthold Lumat LB-9501. IC<sub>50</sub>s obtained were as shown in Table 2.

[0051]

Table 2 IC<sub>50</sub> for various luciferase

Luciferase type	IC <sub>50</sub> (%)
North American firefly	0.014
GENJI firefly luciferase	0.016
HEIKE firefly	0.026

luciferase	
HEIKE I mutant	0.028
HEIKE L mutant	0.028
HIK	0.032
HLK	0.035

[0052]

North American firefly luciferase showed the lowest IC<sub>50</sub> among the three types of wild-type luciferase. That is, North American firefly luciferase was shown to have the lowest resistance to a surfactant. HEIKE firefly luciferase showed the highest IC<sub>50</sub> among the wild-type luciferase. HLK and HIK showed IC<sub>50</sub> higher than those of wild-type HEIKE firefly luciferase and thermostable HEIKE firefly luciferase, suggesting that the resistance was improved by the substitution of an amino acid at the 490-position. Especially HLK showed IC<sub>50</sub> higher than that of HIK, indicating that HLK possesses the best surfactant-resistance.

[0053]

#### Example 5 Method for measuring intracellular ATP

Next, a method for measuring intracellular ATP using the surfactant-resistant luciferase of the present invention will be described.

A standard technique used herein was TCA extraction method wherein intracellular ATP is extracted using trichloroacetic acid (TCA) and the amount of ATP extracted is measured using luciferin-luciferase luminescence reaction. TCA extraction method is excellent in extraction efficiency. Further in TCA extraction method no inhibition of luminescence reaction is caused by TCA because emission is measured after the sample containing TCA is diluted 1:100. Because of this dilution, however, TCA extraction method is complicated and can cause a decrease in the measuring sensitivity.

[0054]

#### 1. Materials

##### (1) Surfactant

Benzalkonium chloride (BAC, Japanese Pharmacopoeia) was used. ATP extraction reagent was prepared by dissolving this surfactant at 0.25% concentration into 25mM Tricine (pH 7.75).

##### (2) Microorganisms

Four strains, *Escherichia coli* (ATCC 25922), *Staphylococcus aureus* (ATCC 25923), *Pseudomonas aeruginosa* (ATCC 27853) and *Enterococcus faecalis* (ATCC 29212) were used.

[0055]

##### (3) Preparation of samples

In standard techniques, a sample, undiluted solution, was prepared by culturing the prescribed microorganisms on a normal broth medium (produced by Eiken chemical Co., Ltd.) at 35°C overnight. In the method of the present invention, a sample diluted solution was prepared by diluting an undiluted solution of the

culture fluid to 1:100 with sterile water.

#### (4) Luciferase

Surfactant-resistant luciferase of the present invention were HIK and HLK. Control surfactant-resistant luciferase types were known luciferase (North American firefly luciferase, GENJI firefly luciferase, HEIKE firefly luciferase, HEIKE I mutant, and HEIKE L mutant).

[0056]

#### (5) Luminescence reagent

Luminescence reagent was prepared by adding various luciferase to solution containing 0.15mM luciferin, 6mM EDTA, 15mM magnesium acetate, 0.2mM dithiothreitol, 0.5% BSA and 25mM HEPES (pH 7.75).

The amount of luciferase to be added was prepared such that the light emission produced when 100  $\mu$ l of  $2 \times 10^{-8}$  M ATP standard solution was added to 100  $\mu$ l of the luminescence reagent would be the same amount of the light emission produced when a luminescence reagent attached to Luciferase LU (Kikkoman Corporation) was used.

[0057]

### 2. Method for measuring intracellular ATP

#### (1) Method of the present invention

ATP extraction reagent 100  $\mu$ l was added to 100  $\mu$ l of a sample. The solution was allowed to stand for 20 seconds at room temperature. Then 100  $\mu$ l of the luminescence reagent was added to this solution. Immediately after addition, the light emission was measured using Lumat LB-9501 produced by Berthold.

#### (2) Standard technique

10 % trichloro acetate solution 100  $\mu$ l was added to 100  $\mu$ l of a sample and the solution was allowed to stand for 1 minute. 25 mM Tricine (pH 7.75) 9.8ml was added to this extract, and then the extract was well stirred. 25 mM Tricine (pH 7.75) and 100  $\mu$ l of a luminescence reagent attached to CheckLite LU (produced by Kikkoman Corporation) were added to 100  $\mu$ l of the sample. Immediately after addition, the light emission was measured using Lumat LB-9501 produced by Berthold.

[0058]

### 3. Results

Tables 3 and 4 show the results. The relative ratio of the light emissions obtained by the use of the luminescence reagents using various luciferase types is also shown in these tables. Here the light emission obtained by the standard technique (TCA extraction method) was defined as 100%.

[0059]

Table 3 Detection of intracellular ATP

Measuring method	E.coli ATCC25922		S.aureus ATCC 25923	
	Measured	Relative	Measured	Relative

	value (RLU)	ratio (%)	value(RLU)	ratio (%)
Standard technique (TCA extraction method)	132794	(100.0)	130220	(100.0)
North American firefly	153	(0.1)	163	(0.1)
GENJI firefly luciferase	463	(0.3)	659	(0.5)
HEIKE firefly luciferase	76082	(57.3)	74019	(56.8)
HEIKE I mutant	47655	(35.9)	50031	(38.4)
HEIKE L mutant	46217	(34.8)	51243	(39.4)
HIK	97073	(73.1)	76533	(58.8)
HLK	87981	(66.3)	72182	(55.4)

[0060]

Table 4 Detection of intracellular ATP

Measuring method	P.aeruginosa ATCC 27853		E.faecalis ATCC 29212	
	Measured value (RLU)	Relative ratio (%)	Measured value(RLU)	Relative ratio (%)
Standard technique (TCA extraction method)	168141	(100.0)	12427	(100.0)
North American firefly	553	(0.3)	113	(0.1)
GENJI firefly luciferase	1503	(0.9)	163	(1.3)
HEIKE firefly luciferase	117096	(69.6)	8132	(65.4)
HEIKE I mutant	80455	(47.8)	4586	(36.9)
HEIKE L mutant	81069	(48.2)	4762	(38.3)
HIK	131134	(78.0)	7914	(63.7)
HLK	131815	(78.4)	7998	(64.4)

[0061]

No emission was observed for the luminescence reagent containing North American firefly luciferase. GENJI firefly luciferase showed weak emission. This is because the luciferase itself was devitalized by the surfactant. Therefore, it was shown that the surfactant at high concentration such as was used in this examination cannot be used as an ATP extraction reagent for the luciferase.

Unlike North American firefly luciferase and GENJI firefly luciferase, HEIKE

firefly luciferase showed emission 60 to 70% of that in TCA extraction method. HEIKE firefly luciferase was shown to possess surfactant-resistance higher than those of North American firefly luciferase and GENJI firefly luciferase.

[0062]

Light emissions from HEIKE L mutant, and HEIKE I mutant which is thermostable HEIKE firefly luciferase were each equivalent to around 40% of that in TCA extraction method, and largely lower than that of wild-type HEIKE firefly luciferase.

Each of the light emission from HIK and HLK, which is surfactant-resistant luciferase of the present invention, respectively was more intense than that from wild-type HEIKE luciferase and thermostable luciferase. Further the light emission in this case was equivalent to 60 to 80% of that in TCA extraction method.

[0063]

HIK and HLK are mutants wherein Glu at the 490-position of HEIKE I and HEIKE L mutants are substituted for Lys, respectively. That is, the introduction of said mutation into the amino acid at the 490-position improved resistance to a surfactant. The sensitivity of HIK and HLK is less affected by ATP extraction reagent even at such a high concentration employed in this examination, suggesting the use of HIK and HLK enable highly accurate measurement.

[0064]

[Advantage of the Invention]

The use of a novel surfactant-resistant luciferase according to the present invention for measuring intracellular ATP allows the detection without a decrease in luciferase activity even in the presence of a surfactant at a high concentration.

[0065]

[Sequence Listing]

SEQ ID NO:1

- (1) Length: 23
- (2) Type: Nucleic acid
- (3) Number of chain: single strand
- (4) Topology: Linear
- (5) Kind: Other nucleic acid, Synthetic DNA primer
- (6) Sequence

TGTTGTA CTT AAGAAAGGAA AAT

[0066]

SEQ ID NO:2

- (1) Length: 23
- (2) Type: Nucleic acid
- (3) Number of chain: single strand
- (4) Topology: Linear
- (5) Kind: Other nucleic acid, Synthetic DNA primer



(6) Sequence

ACAGCTCCCG GAAGCTCACC AGC

[0067]

SEQ ID NO:3

(1) Length: 1644

(2) Type: Nucleic acid

(3) Number of chain: single strand

(4) Topology: Linear

(5) Kind: DNA

(6) feature: Base sequence of luciferase structural gene in pHLfLK

ATG GAA AAC ATG GAG AAC GAT GAA AAT ATT GTG TAT GGT CCT GAA CCA TTT TAC  
CCT ATT GAA GAG GGA TCT GCT GGA GCA CAA TTG CGC AAG TAT ATG GAT CGA TAT  
GCA AAA CTT GGA GCA ATT GCT TTT ACT AAC GCA CTT ACC GGT GTC GAT TAT ACG  
TAC GCC GAA TAC TTA GAA AAA TCA TGC TGT CTA GGA GAG GCT TTA AAG AAT TAT  
GGT TTG GTT GTT GAT GGA AGA ATT GCG TTA TGC AGT GAA AAC TGT GAA GAA TTC  
TTT ATT CCT GTA TTA GCC GGT TTA TTT ATA GGT GTC GGT GTG GCT CCA ACT AAT  
GAG ATT TAC ACT CTA CGT GAA TTG GTT CAC AGT TTA GGC ATC TCT AAG CCA ACA  
ATT GTA TTT AGT TCT AAA AAA GGA TTA GAT AAA GTT ATA ACT GTA CAA AAA ACG  
GTA ACT GCT ATT AAA ACC ATT GTT ATA TTG GAC AGC AAA GTG GAT TAT AGA GGT  
TAT CAA TCC ATG GAC AAC TTT ATT AAA AAA AAC ACT CCA CAA GGT TTC AAA GGA  
TCA AGT TTT AAA ACT GTA GAA GTT AAC CGC AAA GAA CAA GTT GCT CTT ATA ATG  
AAC TCT TCG GGT TCA ACC GGT TTG CCA AAA GGT GTG CAA CTT ACT CAT GAA AAT  
TTG GTC ACT AGA TTT TCT CAC GCT AGA GAT CCA ATT TAT GGA AAC CAA GTT TCA  
CCA GGC ACG GCT ATT TTA ACT GTA GTA CCA TTC CAT CAT GGT TTT GGT ATG TTT  
ACT ACT TTA GGC TAT CTA ACT TGT GGT TTT CGT ATT GTC ATG TTA ACG AAA TTT  
GAC GAA GAG ACT TTT TTA AAA ACA CTG CAA GAT TAC AAA TGT TCA AGC GTT ATT

CTT GTA CCG ACT TTG TTT GCA ATT CTT AAT AGA AGT GAA TTA CTC GAT AAA TAT  
 GAT TTA TCA AAT TTA GTT GAA ATT GCA TCT GGC GGA GCA CCT TTA TCT AAA GAA  
 ATT GGT GAA GCT GTT GCT AGA CGT TTT AAT TTA CCG GGT GTT CGT CAA GGC TAT  
 GGT TTA ACA GAA ACA ACC TCT GCA ATT ATT ATC ACA CCG GAA GGC GAT GAT AAA  
 CCA GGT GCT TCT GGC AAA GTT GTG CCA TTA TTT AAA GCA AAA GTT ATC GAT CTT  
 GAT ACT AAA AAA ACT TTG GGC CCG AAC AGA CGT GGA GAA GTT TGT GTA AAG GGT  
 CCT ATG CTT ATG AAA GGT TAT GTA GAT AAT CCA GAA GCA ACA AGA GAA ATC ATA  
 GAT GAA GAA GGT TGG TTG CAC ACA GGA GAT ATT GGG TAT TAC GAT GAA GAA AAA  
 CAT TTC TTT ATC GTG GAT CGT TTG AAG TCT TTA ATC AAA TAC AAA GGA TAT CAA  
 GTA CCA CCT GCT GAA TTA GAA TCT GTT CTT TTG CAA CAT CCA AAT ATT TTT GAT  
 GCC GGC GTT GCT GGC GTT CCA GAT CCT ATA GCT GGT GAG CTT CCG GGA GCT GTT  
 GTT GTA CTT AAG AAA GGA AAA TCT ATG ACT GAA AAA GAA GTA ATG GAT TAC GTT  
 GCT AGT CAA GTT TCA AAT GCA AAA CGT TTG CGT GGT GGT GTC CGT TTT GTG GAC  
 GAA GTA CCT AAA GGT CTC ACT GGT AAA ATT GAC GGT AAA GCA ATT AGA GAA ATA  
 CTG AAG AAA CCA GTT GCT AAG ATG 3'

SEQ ID NO:4

- (1) Length: 548
- (2) Type: Amino acid
- (3) Number of chain: single strand
- (4) Topology: Linear
- (5) Kind: peptide
- (6) feature: Amino acid sequence of luciferase structural gene in pHLfLK

Met Glu Asn Met Glu Asn Asp Glu Asn Ile Val Tyr Gly Pro Glu Pro Phe Tyr  
 Pro Ile Glu Glu Gly Ser Ala Gly Ala Gln Leu Arg Lys Tyr Met Asp Arg Tyr  
 Ala Lys Leu Gly Ala Ile Ala Phe Thr Asn Ala Leu Thr Gly Val Asp Tyr Thr

Tyr Ala Glu Tyr Leu Glu Lys Ser Cys Cys Leu Gly Glu Ala Leu Lys Asn Tyr  
Gly Leu Val Val Asp Gly Arg Ile Ala Leu Cys Ser Glu Asn Cys Glu Glu Phe  
Phe Ile Pro Val Leu Ala Gly Leu Phe Ile Gly Val Gly Val Ala Pro Thr Asn  
Glu Ile Tyr Thr Leu Arg Glu Leu Val His Ser Leu Gly Ile Ser Lys Pro Thr  
Ile Val Phe Ser Ser Lys Lys Gly Leu Asp Lys Val Ile Thr Val Gln Lys Thr  
Val Thr Ala Ile Lys Thr Ile Val Ile Leu Asp Ser Lys Val Asp Tyr Arg Gly  
Tyr Gln Ser Met Asp Asn Phe Ile Lys Lys Asn Thr Pro Gln Gly Phe Lys Gly  
Ser Ser Phe Lys Thr Val Glu Val Asn Arg Lys Glu Gln Val Ala Leu Ile Met  
Asn Ser Ser Gly Ser Thr Gly Leu Pro Lys Gly Val Gln Leu Thr His Glu Asn  
Leu Val Thr Arg Phe Ser His Ala Arg Asp Pro Ile Tyr Gly Asn Gln Val Ser  
Pro Gly Thr Ala Ile Leu Thr Val Val Pro Phe His His Gly Phe Gly Met Phe  
Thr Thr Leu Gly Tyr Leu Thr Cys Gly Phe Arg Ile Val Met Leu Thr Lys Phe  
Asp Glu Glu Thr Phe Leu Lys Thr Leu Gln Asp Tyr Lys Cys Ser Ser Val Ile  
Leu Val Pro Thr Leu Phe Ala Ile Leu Asn Arg Ser Glu Leu Leu Asp Lys Tyr  
Asp Leu Ser Asn Leu Val Glu Ile Ala Ser Gly Gly Ala Pro Leu Ser Lys Glu  
Ile Gly Glu Ala Val Ala Arg Arg Phe Asn Leu Pro Gly Val Arg Gln Gly Tyr  
Gly Leu Thr Glu Thr Thr Ser Ala Ile Ile Ile Thr Pro Glu Gly Asp Asp Lys  
Pro Gly Ala Ser Gly Lys Val Val Pro Leu Phe Lys Ala Lys Val Ile Asp Leu  
Asp Thr Lys Lys Thr Leu Gly Pro Asn Arg Arg Gly Glu Val Cys Val Lys Gly  
Pro Met Leu Met Lys Gly Tyr Val Asp Asn Pro Glu Ala Thr Arg Glu Ile Ile  
Asp Glu Glu Gly Trp Leu His Thr Gly Asp Ile Gly Tyr Tyr Asp Glu Glu Lys



His Phe Phe Ile Val Asp Arg Leu Lys Ser Leu Ile Lys Tyr Lys Gly Tyr Gln  
Val Pro Pro Ala Glu Leu Glu Ser Val Leu Leu Gln His Pro Asn Ile Phe Asp  
Ala Gly Val Ala Gly Val Pro Asp Pro Ile Ala Gly Glu Leu Pro Gly Ala Val  
Val Val Leu Lys Lys Gly Lys Ser Met Thr Glu Lys Glu Val Met Asp Tyr Val  
Ala Ser Gln Val Ser Asn Ala Lys Arg Leu Arg Gly Gly Val Arg Phe Val Asp  
Glu Val Pro Lys Gly Leu Thr Gly Lys Ile Asp Gly Lys Ala Ile Arg Glu Ile  
Leu Lys Lys Pro Val Ala Lys Met

[0069]

SEQ ID NO:5

(1) Length: 1644

(2) Type: Nucleic acid

(3) Number of chain: single strand

(4) Topology: Linear

(5) Kind: DNA

(6) feature: Base sequence of luciferase structural gene in pHLfIK

ATG GAA AAC ATG GAG AAC GAT GAA AAT ATT GTG TAT GGT CCT GAA CCA TTT TAC  
CCT ATT GAA GAG GGA TCT GCT GGA GCA CAA TTG CGC AAG TAT ATG GAT CGA TAT  
GCA AAA CTT GGA GCA ATT GCT TTT ACT AAC GCA CTT ACC GGT GTC GAT TAT ACG  
TAC GCC GAA TAC TTA GAA AAA TCA TGC TGT CTA GGA GAG GCT TTA AAG AAT TAT  
GGT TTG GTT GTT GAT GGA AGA ATT GCG TTA TGC AGT GAA AAC TGT GAA GAA TTC  
TTT ATT CCT GTA TTA GCC GGT TTA TTT ATA GGT GTC GGT GTG GCT CCA ACT AAT  
GAG ATT TAC ACT CTA CGT GAA TTG GTT CAC AGT TTA GGC ATC TCT AAG CCA ACA  
ATT GTA TTT AGT TCT AAA AAA GGA TTA GAT AAA GTT ATA ACT GTA CAA AAA ACG  
GTA ACT GCT ATT AAA ACC ATT GTT ATA TTG GAC AGC AAA GTG GAT TAT AGA GGT  
TAT CAA TCC ATG GAC AAC TTT ATT AAA AAA AAC ACT CCA CAA GGT TTC AAA GGA  
TCA AGT TTT AAA ACT GTA GAA GTT AAC CGC AAA GAA CAA GTT GCT CTT ATA ATG

AAC TCT TCG GGT TCA ACC GGT TTG CCA AAA GGT GTG CAA CTT ACT CAT GAA AAT  
ATC GTC ACT AGA TTT TCT CAC GCT AGA GAT CCA ATT TAT GGA AAC CAA GTT TCA  
CCA GGC ACG GCT ATT TTA ACT GTA GTA CCA TTC CAT CAT GGT TTT GGT ATG TTT  
ACT ACT TTA GGC TAT CTA ACT TGT GGT TTT CGT ATT GTC ATG TTA ACG AAA TTT  
GAC GAA GAG ACT TTT TTA AAA ACA CTG CAA GAT TAC AAA TGT TCA AGC GTT ATT  
CTT GTA CCG ACT TTG TTT GCA ATT CTT AAT AGA AGT GAA TTA CTC GAT AAA TAT  
GAT TTA TCA AAT TTA GTT GAA ATT GCA TCT GGC GGA GCA CCT TTA TCT AAA GAA  
ATT GGT GAA GCT GTT GCT AGA CGT TTT AAT TTA CCG GGT GTT CGT CAA GGC TAT  
GGT TTA ACA GAA ACA ACC TCT GCA ATT ATT ATC ACA CCG GAA GGC GAT GAT AAA  
CCA GGT GCT TCT GGC AAA GTT GTG CCA TTA TTT AAA GCA AAA GTT ATC GAT CTT  
GAT ACT AAA AAA ACT TTG GGC CCG AAC AGA CGT GGA GAA GTT TGT GTA AAG GGT  
CCT ATG CTT ATG AAA GGT TAT GTA GAT AAT CCA GAA GCA ACA AGA GAA ATC ATA  
GAT GAA GAA GGT TGG TTG CAC ACA GGA GAT ATT GGG TAT TAC GAT GAA GAA AAA  
CAT TTC TTT ATC GTG GAT CGT TTG AAG TCT TTA ATC AAA TAC AAA GGA TAT CAA  
GTA CCA CCT GCT GAA TTA GAA TCT GTT CTT TTG CAA CAT CCA AAT ATT TTT GAT  
GCC GGC GTT GCT GGC GTT CCA GAT CCT ATA GCT GGT GAG CTT CCG GGA GCT GTT  
GTT GTA CTT AAG AAA GGA AAA TCT ATG ACT GAA AAA GAA GTA ATG GAT TAC GTT  
GCT AGT CAA GTT TCA AAT GCA AAA CGT TTG CGT GGT GGT GTC CGT TTT GTG GAC  
GAA GTA CCT AAA GGT CTC ACT GGT AAA ATT GAC GGT AAA GCA ATT AGA GAA ATA  
CTG AAG AAA CCA GTT GCT AAG ATG 3'

[0070]

SEQ ID NO:6

(1) Length: 548

- (2) Type: Amino acid
- (3) Number of chain: single strand
- (4) Topology: Linear
- (5) Kind: DNA
- (6) feature: Amino acid sequence of luciferase structural gene in pHLfIK

Met Glu Asn Met Glu Asn Asp Glu Asn Ile Val Tyr Gly Pro Glu Pro Phe Tyr  
Pro Ile Glu Glu Gly Ser Ala Gly Ala Gln Leu Arg Lys Tyr Met Asp Arg Tyr  
Ala Lys Leu Gly Ala Ile Ala Phe Thr Asn Ala Leu Thr Gly Val Asp Tyr Thr  
Tyr Ala Glu Tyr Leu Glu Lys Ser Cys Cys Leu Gly Glu Ala Leu Lys Asn Tyr  
Gly Leu Val Val Asp Gly Arg Ile Ala Leu Cys Ser Glu Asn Cys Glu Glu Phe  
Phe Ile Pro Val Leu Ala Gly Leu Phe Ile Gly Val Gly Val Ala Pro Thr Asn  
Glu Ile Tyr Thr Leu Arg Glu Leu Val His Ser Leu Gly Ile Ser Lys Pro Thr  
Ile Val Phe Ser Ser Lys Lys Gly Leu Asp Lys Val Ile Thr Val Gln Lys Thr  
Val Thr Ala Ile Lys Thr Ile Val Ile Leu Asp Ser Lys Val Asp Tyr Arg Gly  
Tyr Gln Ser Met Asp Asn Phe Ile Lys Lys Asn Thr Pro Gln Gly Phe Lys Gly  
Ser Ser Phe Lys Thr Val Glu Val Asn Arg Lys Glu Gln Val Ala Leu Ile Met  
Asn Ser Ser Gly Ser Thr Gly Leu Pro Lys Gly Val Gln Leu Thr His Glu Asn  
Ile Val Thr Arg Phe Ser His Ala Arg Asp Pro Ile Tyr Gly Asn Gln Val Ser  
Pro Gly Thr Ala Ile Leu Thr Val Val Pro Phe His His Gly Phe Gly Met Phe  
Thr Thr Leu Gly Tyr Leu Thr Cys Gly Phe Arg Ile Val Met Leu Thr Lys Phe  
Asp Glu Glu Thr Phe Leu Lys Thr Leu Gln Asp Tyr Lys Cys Ser Ser Val Ile  
Leu Val Pro Thr Leu Phe Ala Ile Leu Asn Arg Ser Glu Leu Leu Asp Lys Tyr  
Asp Leu Ser Asn Leu Val Glu Ile Ala Ser Gly Gly Ala Pro Leu Ser Lys Glu  
Ile Gly Glu Ala Val Ala Arg Arg Phe Asn Leu Pro Gly Val Arg Gln Gly Tyr

Gly Leu Thr Glu Thr Thr Ser Ala Ile Ile Ile Thr Pro Glu Gly Asp Asp Lys  
Pro Gly Ala Ser Gly Lys Val Val Pro Leu Phe Lys Ala Lys Val Ile Asp Leu  
Asp Thr Lys Lys Thr Leu Gly Pro Asn Arg Arg Gly Glu Val Cys Val Lys Gly  
Pro Met Leu Met Lys Gly Tyr Val Asp Asn Pro Glu Ala Thr Arg Glu Ile Ile  
Asp Glu Glu Gly Trp Leu His Thr Gly Asp Ile Gly Tyr Tyr Asp Glu Glu Lys  
His Phe Phe Ile Val Asp Arg Leu Lys Ser Leu Ile Lys Tyr Lys Gly Tyr Gln  
Val Pro Pro Ala Glu Leu Glu Ser Val Leu Leu Gln His Pro Asn Ile Phe Asp  
Ala Gly Val Ala Gly Val Pro Asp Pro Ile Ala Gly Glu Leu Pro Gly Ala Val  
Val Val Leu Lys Lys Gly Lys Ser Met Thr Glu Lys Glu Val Met Asp Tyr Val  
Ala Ser Gln Val Ser Asn Ala Lys Arg Leu Arg Gly Gly Val Arg Phe Val Asp  
Glu Val Pro Lys Gly Leu Thr Gly Lys Ile Asp Gly Lys Ala Ile Arg Glu Ile  
Leu Lys Lys Pro Val Ala Lys Met

[Brief description of the drawings]

[Figure 1] Figure 1 shows a production processes for a mutant luciferase HIK.

[Figure 2] Figure 2 shows change with time of light emission from natural type luciferase.

[Figure 3] Figure 3 shows change with time of light emission from mutant luciferase.

[Document Name] Abstract

[Summary]

[Means for Solving the Problem] The present invention relates to luciferase having resistance to a surfactant and a method for measuring intracellular ATP which is characterized in that the luciferase having resistance to a surfactant is used in this method comprising the steps of: a first step wherein ATP is extracted from cells in a sample; a second step wherein light emission is produced by adding a luminescence reagent containing luciferase to the extracted ATP solution; and a third step wherein the light emission is measured.

[Advantageous Effect] The present invention provides novel liciferase having resistance to a surfactant and it is possible to measure cellular ATP without the decrease of the catalytic activity of bioluminescence reaction in the presence of a surfactant by measuring cellular ATP with the novel luciferase.

[Selected Figure] None